Suppression of Natural Killer Cells by Sorafenib Contributes to Prometastatic Effects in Hepatocellular Carcinoma

Sorafenib decreases proliferation and induces apoptosis of prostate cancer cells by inhibition of the androgen receptor and Akt signaling pathways

(2012) Su Jung Oh et al.   ENDOCRINE-RELATED CANCER

Global cancer statistics

(2011) Ahmedin Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma

(2011) Wei-Tien Tai et al.   JOURNAL OF HEPATOLOGY

Increasing Incidence of Brain Metastasis in Patients with Advanced Hepatocellular Carcinoma in the Era of Antiangiogenic Targeted Therapy

(2011) Y.-Y. Shao et al.   ONCOLOGIST

Depletion of Tumor-Associated Macrophages Enhances the Effect of Sorafenib in Metastatic Liver Cancer Models by Antimetastatic and Antiangiogenic Effects

(2010) W. Zhang et al.   CLINICAL CANCER RESEARCH

Cutting Edge: NKp80 Uses an Atypical Hemi-ITAM To Trigger NK Cytotoxicity

(2010) K. M. Dennehy et al.   JOURNAL OF IMMUNOLOGY

Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes

(2009) C Alfaro et al.   BRITISH JOURNAL OF CANCER

Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis

(2009) John M.L. Ebos et al.   CANCER CELL

Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis

(2009) Marta Pàez-Ribes et al.   CANCER CELL

The Kinase Inhibitors Sunitinib and Sorafenib Differentially Affect NK Cell Antitumor Reactivity In Vitro

(2009) M. Krusch et al.   JOURNAL OF IMMUNOLOGY

Rapamycin, But Not Cyclosporine or FK506, Alters Natural Killer Cell Function

(2009) Lu-En Wai et al.   TRANSPLANTATION

Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses

(2008) M. M. Hipp et al.   BLOOD

Biological characteristics of fluorescent protein-expressing human hepatocellular carcinoma xenograft model in nude mice

(2008) Bi-Wei Yang et al.   EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY

Sorafenib for liver cancer: the horizon broadens

(2008) Philip Johnson et al.   LANCET ONCOLOGY

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

(2008) Ann-Lii Cheng et al.   LANCET ONCOLOGY

Sorafenib inhibits activation of human peripheral blood T cells by targeting LCK phosphorylation

(2008) W Zhao et al.   LEUKEMIA

Functions of natural killer cells

(2008) Eric Vivier et al.   NATURE IMMUNOLOGY

Sorafenib in Advanced Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   NEW ENGLAND JOURNAL OF MEDICINE